We’re very pleased that Spiro PD can help hospitals reduce readmissions and improve the quality of life for their patients.
Allentown, Pennsylvania (PRWEB) October 17, 2012
Enforcing revised regulations effective October 1, 2012, The Centers for Medicare & Medicaid Services is now imposing stricter penalties on hospitals that have higher percentages of patients readmitted due to complications within 30 days of discharge. The penalties are part of a broader push under President Obama's health care initiative to improve quality of care while maintaining or enhancing cost-effectiveness.
For patients with respiratory conditions – asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, cystic fibrosis (CF), and lung transplants – hospitals across the country have been using Spiro PD Personal Spirometer to provide early detection to help prevent patient readmissions and avoid costly Medicare penalties.
Spiro PD allows patients to easily and accurately track their lung function trends anytime, anywhere: at home, school, work, or on vacation. This helps patients anticipate and prevent respiratory exacerbations, thus reducing the likelihood of having to be readmitted to the hospital for treatment. It also helps decrease expensive ER visits and hospital stays.
According to a Johns Hopkins University study, home spirometry detected a decline in lung function 15.6 days before patients felt the symptoms and sought medical care. Spiro PD’s ability to note early detection of decreased lung function can keep chronic respiratory patients out of hospitals by catching problems before they worsen.
Says Wayne Meng, Founder, Chief Executive Officer, and President of PMD Healthcare, the maker of Spiro PD, “The continuing rise of healthcare costs is a concern to us all. We’re very pleased that Spiro PD can help hospitals reduce readmissions and improve the quality of life for their patients.”
For more information about all the advantages that Spiro PD offers people with respiratory conditions, please visit http://www.SpiroPD.com.
About Spiro PD
“Spiro" stands for spirometer, a device used to measure air entering and leaving the lungs; "PD" stands for personal device. Spiro PD is the first personal spirometer that enables people with lung diseases – asthma, COPD, CF, and lung transplants – to easily and accurately monitor their breathing anytime and anywhere.
Spiro PD tracks lung function trends to help patients anticipate and prevent exacerbations and asthma attacks, which helps reduce expensive emergency room visits and hospital stays. According to a study of cystic fibrosis patients at Johns Hopkins University, home spirometry detected decreased lung function 15.6 days before patients felt symptoms and sought medical care.(1)
Spiro PD enhances medication adherence. The medication alarm helps patients remember to take their medicine. The medication history provides a time stamp to show doctors that patients have been following their therapy.
Spiro PD also allows patients to set alarms reminding them to perform spirometry tests and do breathing exercises. Plus, patients can quickly upload data to their computer and share it with their doctor.
Spiro PD is cleared by the FDA for home use by the patient to test lung function in children, adolescents, and adults. Many insurance companies cover the cost of Spiro PD.
Spiro PD meets American Thoracic Society (ATS) and European Respiratory Society (ERS) standards. Spiro PD is also certified with the CE mark for the European Union (EU).
For more information, visit http://www.SpiroPD.com.
About PMD Healthcare, Inc.
PMD Healthcare, manufacturer of Spiro PD, is dedicated to creating innovative, easy-to-use, portable, and affordable personal medical devices that empower people worldwide to improve their healthcare and quality of life. For more information about PMD Healthcare and Spiro PD, please visit http://www.SpiroPD.com.
1. West NE, Boyle MP, Mogayzel PJ, Riekert KA, Lechtzin N. The ability of home spirometry and symptom monitoring to predict exacerbations in cystic fibrosis. Pediatric Pulmonology 2009; Vol. 34, S32 “Poster Session Abstract” poster 376.